Clostridium difficile colitis: pathogenesis and host defence
about
Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and ObesityInterspecies Interactions between Clostridium difficile and Candida albicansA Clostridium difficile-Specific, Gel-Forming Protein Required for Optimal Spore GerminationIdentification of Highly Specific Diversity-Oriented Synthesis-Derived Inhibitors of Clostridium difficile.Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.Disparate subcellular location of putative sortase substrates in Clostridium difficile.The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens.Revisiting the role of Csp family proteins in regulating Clostridium difficile spore germination.RNA-mediated signal perception in pathogenic bacteria.Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?Clostridium difficile Infection and the Role of Adaptive Immunity in the Microbiome.The alternative sigma factor σB plays a crucial role in adaptive strategies of Clostridium difficile during gut infection.The Conserved Spore Coat Protein SpoVM Is Largely Dispensable in Clostridium difficile Spore FormationSNP-ing out the differences: Investigating differences between Clostridium difficile lab strains.Interactions between Bacteria and Bile Salts in the Gastrointestinal and Hepatobiliary Tracts.Analysis of killing of growing cells and dormant and germinated spores of Bacillus species by black silicon nanopillars.The bacterial virulence factor CagA induces microbial dysbiosis that contributes to excessive epithelial cell proliferation in the Drosophila gut.Lauric Acid Is an Inhibitor of Clostridium difficile Growth in Vitro and Reduces Inflammation in a Mouse Infection Model.In silico analysis of antibiotic-induced Clostridium difficile infection: Remediation techniques and biological adaptations.Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection.Microbiota-derived Metabolic Factors Reduce Campylobacteriosis in Mice.Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy.Outcomes associated with Clostridium difficile infection in patients with chronic liver disease.Type IV Pili Promote Clostridium difficile Adherence and Persistence in a Mouse Model of Infection.Clostridium difficile: A bad bug goes into defensive mode.TPL2 is a key regulator of intestinal inflammation in C. difficile infection.Food-Associated Stress Primes Foodborne Pathogens for the Gastrointestinal Phase of InfectionAn update on the human and animal enteric pathogen Clostridium perfringensNew Insights Into Functions and Possible Applications of CRISPR-Cas SystemZinc Deficiency and the Recurrence of Infection after Fecal Microbiota Transplant: A Retrospective Cohort StudyBiofilm: Remodeling Metabolism and Cell Surface to Build a Sparse and Heterogeneously Aggregated Architecture
P2860
Q28070349-39C5210A-8294-4ABA-B8BE-9A798298968AQ28821706-A04586DF-A01E-4920-9A79-263F97BE43A6Q37590711-374D054F-8840-43BE-9055-D48C5E9665F1Q38953573-7CE09A81-5C00-46ED-B2CF-4189F6370A9DQ39197564-FE5DC21A-1356-4686-A797-00E5242860BBQ39347327-C93F425A-B471-4C9E-A5F6-5E6926696ECDQ40063718-4752221F-CE19-473B-9880-EB334C90AE84Q40065922-2F3A8132-3F5A-4844-A67D-D0B3D2B0B777Q40100649-F1E05B62-7D3D-4C99-88E4-AC7BDAE62B66Q40110130-3783736C-DE1A-49AF-93F7-D007FB1B5C32Q40155716-E6C7AB30-C4EF-49F8-AEE1-4E8A53850D3AQ40332943-9608B2E2-A027-4FF5-9787-34BD978D44A9Q41676526-FB98C3E3-894B-474E-9B1B-A0EF056E57F1Q42072636-938C1496-CCD6-4D98-8021-2A67F1B42925Q42372550-D87A75BC-FEB7-49FA-8551-62BB493086ACQ47100844-E31DE8A2-B0C6-46BE-8880-D8AC35CD4AF0Q47156406-263E2F07-10DE-484C-87F7-07E8BAED1B74Q49368088-1AAEB8B0-ACD2-4F7C-8D3F-6640B40E3480Q49925385-C318039E-18AF-468E-9151-C5D2BFFDBA6FQ50016954-068FC364-57A9-4CEB-8686-A7A1615165E2Q50058466-01FC8E87-85DF-4ED9-91A1-E62D8B2016F7Q51740367-D2CE5BD0-F533-42B1-9983-4EC6DE83F0B1Q54217863-EB4FB9E7-CC66-4C34-BDCD-2FABDF449C70Q54266191-61C3E0ED-CBB1-4231-BDA5-8772CEA85E55Q54732607-01FCF955-EBE3-4CD9-80BA-332D740583BFQ54977805-C06EE352-D40E-4B15-A6AE-C95F381D1F05Q57111166-8C3586CA-C4A1-41B1-88BD-4D1F8714E7E1Q57170565-ECDF0429-601B-4E8D-B011-BBDC367665D6Q57173950-5A20F58A-756C-4955-A774-4EE41722F1C7Q58576978-61F657F4-F646-4BA5-9DC6-F078A1FD0837Q58746416-36A101DB-D2F5-447E-9148-4CFA8059BAA2
P2860
Clostridium difficile colitis: pathogenesis and host defence
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Clostridium difficile colitis: pathogenesis and host defence
@ast
Clostridium difficile colitis: pathogenesis and host defence
@en
type
label
Clostridium difficile colitis: pathogenesis and host defence
@ast
Clostridium difficile colitis: pathogenesis and host defence
@en
prefLabel
Clostridium difficile colitis: pathogenesis and host defence
@ast
Clostridium difficile colitis: pathogenesis and host defence
@en
P2093
P2860
P356
P1476
Clostridium difficile colitis: pathogenesis and host defence
@en
P2093
Eric G Pamer
Michael C Abt
Peter T McKenney
P2860
P2888
P304
P356
10.1038/NRMICRO.2016.108
P407
P577
2016-08-30T00:00:00Z